Neuromyelitis Optica Spectrum Disorder  >>  Enspryng (satralizumab) 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enspryng (satralizumab) / Roche
SAkuraBonsai, NCT05269667: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Terminated
4
4
Europe, Canada, Japan, US, RoW
Satralizumab 120 mg
Hoffmann-La Roche, Chugai Pharmaceutical Co.
Neuromyelitis Optica Spectrum Disorder, NMOSD
10/23
10/23
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento

Not yet recruiting
3
100
Europe
satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng
F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,รจ un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10]
 
 
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder

Not yet recruiting
3
8
Europe
Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Completed
3
119
Europe, Canada, Japan, US, RoW
satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder
05/24
05/24
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Recruiting
3
8
Europe, US, RoW
Satralizumab
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder, NMOSD
03/27
09/29

Download Options